Ignite Creation Date:
2024-05-06 @ 3:19 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04592653
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-07
First Post:
2020-08-24
Brief Title:
Less Frequent IV Dosing Tumor Microenvironment TME Study of Nemvaleukin Alfa ALKS 4230 Monotherapy and in Combination With Pembrolizumab ARTISTRY-3
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Organization Data
Organization:
Mural Oncology Inc
Class:
INDUSTRY
Study ID:
ALKS 4230-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Mural Oncology Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None